News

Investment

Constructively disruptive – tackling atherosclerosis through disease reversal

Tobias Reichmuth – the longevity market starts now

Sound opportunity: Hearing Diagnostics £1.1m funding augurs market breakthrough

Edinburgh-based healthtech company moves towards commercialisation in the domestic and US markets following a £1.1m Archangels-led fundraise.

New study expands range of potential Alzheimer’s drugs

Coinbase CEO to plough $54 million into longevity research

Blood age clocks can revolutionise the insurance underwriting process

Genflow Bio scoops €250k to accelerate antiaging gene therapy platform

Former Credit Suisse CEO has Human Longevity investment in his sights

Cleara Biotech closes $2.5m seed financing to advance senotherapeutics

Colossal Biosciences spin out Form Bio lands $30 million for breakthrough computational life sciences platform

Hevolution CEO on how to spend $1 billion a year on longevity

Hevolution Foundation commits $2 million to accelerate research in neglected areas of healthspan science

Revel Pharma – harnessing the power of therapeutic enzymes

Phil Newman to speak at Rejuvenation Startup Summit 2022

Insilico appoints co-CEO in readiness for clinical data test

Transforming Ottawa into the wellness & longevity capital of North America

Longevity startup Avea closes CHF 2.5 million in first financing round

New neurotech report examines how we are unlocking the brain’s longevity potential

Longevity “top of my agenda” says Silicon Valley Bank VP

“Whole-body mitochondrial transfusion” start-up lands funding

Harvard spin-off Cellvie Inc closes $5M seed round

Senolytic start-up gears up for clinical trials

Gerostate Alpha: “Our phenotype is lifespan”

Committee blasts UK Government approach to aging

R42 launches $16 million Longevity fund

Clene goes for gold, and goes public

A year in Longevity: different perspectives

A year in Longevity: founders’ perspectives

A year in Longevity: science perspectives

Human Longevity and the Final Frontier

BioAge CEO: “It’s all about the data.”

BioAge lands $90 million; gears up for clinical trials in 2021

Find us here ...

© Copyright 2022 FIRST LONGEVITY Limited. All rights reserved. FIRST LONGEVITY

First Longevity Ltd is an appointed representative of Prospect Capital Ltd which is authorised and regulated by the Financial Conduct Authority.
The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding and knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.